People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure,
atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent …

Post‐transplant diabetes mellitus (PTDM) shows a relationship with risk factors including
obesity and tacrolimus‐based immunosuppression, which decreases pancreatic insulin …

Background SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2
diabetes and have been shown to reduce body weight. However, it is unclear which body …

Background. The efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i)
have not been investigated in kidney transplant recipients (KTRs) with diabetes. We …

Diabetic kidney disease (DKD) is a major complication of diabetes mellitus (DM), affecting
over one-third of type 1 and nearly half of type 2 diabetes patients. As the leading cause of …

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibition has been shown to reduce
cardiovascular mortality and preserve kidney function in patients with type 2 diabetes …

Cardiovascular disease remains a leading cause of death and morbidity in kidney transplant
recipients and a common reason for post-transplant hospitalization. Several traditional and …

Several recent randomized controlled trials (RCTs) have demonstrated the wide clinical
application of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in improving kidney and …

Background: The objective of this systematic review was to evaluate the efficacy and safety
profiles of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for treatment of diabetes …

Background Sodium–glucose cotransporter-2 inhibitors (SGLT2is) have cardioprotective
and renoprotective effects. However, experience with SGLT2is in diabetic kidney transplant …